Free Trial

Crestwood Advisors Group LLC Invests $464,000 in Repligen Corporation (NASDAQ:RGEN)

Repligen logo with Medical background

Crestwood Advisors Group LLC bought a new position in Repligen Corporation (NASDAQ:RGEN - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,647 shares of the biotechnology company's stock, valued at approximately $464,000.

Other hedge funds have also made changes to their positions in the company. KBC Group NV grew its position in Repligen by 14.9% during the 1st quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock worth $324,000 after purchasing an additional 329 shares in the last quarter. LPL Financial LLC lifted its stake in shares of Repligen by 47.6% during the fourth quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock valued at $4,873,000 after acquiring an additional 10,395 shares during the period. Signaturefd LLC increased its holdings in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the last quarter. GAMMA Investing LLC boosted its stake in Repligen by 40.1% during the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 274 shares during the last quarter. Finally, Zions Bancorporation N.A. grew its holdings in Repligen by 48.9% during the fourth quarter. Zions Bancorporation N.A. now owns 14,079 shares of the biotechnology company's stock valued at $2,027,000 after purchasing an additional 4,626 shares during the period. Institutional investors own 97.64% of the company's stock.

Repligen Stock Down 0.1%

NASDAQ:RGEN traded down $0.13 on Friday, hitting $121.74. The stock had a trading volume of 950,629 shares, compared to its average volume of 754,837. The firm's fifty day simple moving average is $123.58 and its two-hundred day simple moving average is $137.33. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The stock has a market cap of $6.84 billion, a P/E ratio of -270.53, a price-to-earnings-growth ratio of 2.27 and a beta of 1.11.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.28 EPS. Analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of research reports. Evercore ISI decreased their price objective on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Barclays started coverage on Repligen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price objective on the stock. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a research note on Tuesday, April 29th. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 target price on the stock in a research report on Tuesday, July 22nd. Finally, Canaccord Genuity Group lowered their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, Repligen currently has an average rating of "Moderate Buy" and an average price target of $169.92.

View Our Latest Stock Report on Repligen

About Repligen

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Should You Invest $1,000 in Repligen Right Now?

Before you consider Repligen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.

While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines